Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Sees Large Drop in Short Interest

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the target of a significant decrease in short interest during the month of July. As of July 31st, there was short interest totaling 199,838 shares, a decrease of 65.2% from the July 15th total of 574,897 shares. Currently, 5.9% of the shares of the company are short sold. Based on an average daily trading volume, of 5,642,637 shares, the short-interest ratio is currently 0.0 days.

Institutional Investors Weigh In On Catheter Precision

An institutional investor recently bought a new position in Catheter Precision stock. Millennium Management LLC bought a new position in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned about 2.08% of Catheter Precision at the end of the most recent quarter. Hedge funds and other institutional investors own 20.34% of the company’s stock.

Catheter Precision Stock Performance

VTAK traded down $0.02 during trading on Friday, reaching $0.27. 500,612 shares of the company’s stock were exchanged, compared to its average volume of 4,577,982. The company has a market capitalization of $985,530.00, a P/E ratio of -0.02 and a beta of -1.00. The company has a quick ratio of 0.06, a current ratio of 0.06 and a debt-to-equity ratio of 0.35. The business has a 50 day moving average price of $0.68 and a 200 day moving average price of $1.05. Catheter Precision has a fifty-two week low of $0.23 and a fifty-two week high of $4.31.

Catheter Precision (NYSEAMERICAN:VTAK) last posted its earnings results on Monday, May 18th. The company reported ($1.39) EPS for the quarter, topping the consensus estimate of ($20.90) by $19.51. The business had revenue of $0.43 million during the quarter, compared to the consensus estimate of $1.60 million. Catheter Precision had a negative return on equity of 76.51% and a negative net margin of 1,297.56%.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.